ORLANDO — In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.
Eichenbaum noted that tyrosine kinase inhibitors and gene therapy programs are moving toward being commercial products in the near future, adding to the treatment options available to patients with wet AMD.
“I’m excited to see those programs read out and get the most effective, safe therapies out to help our patients,” Eichenbaum, of Retina Vitreous Associates of Florida, told Healio.